News & Events

Poster: 14th ÖGMBT Annual Meeting 2022

By September 26, 2022October 5th, 2022No Comments

VIENNA, September 26th:

BiomeDx presented last week at the ÖGMBT (https://oegmbt.at/events/annual-meeting) in Vienna the poster entitled “Deconfounding the intestinal microbiome signature of responders versus non-responders to immune checkpoint inhibitors”. The abstract was selected for a poster presentation and a flash talk. This work comprised a careful examination of the published datasets regarding the impact of the intestinal microbiome on response to immune checkpoint inhibitors and investigated the impact of biological and technical confounders on the microbial signature associated to ICI response.

About BiomeOne®
BiomeOne has been CE-IVD marked in May 2022, and is now available for purchase in our website. The test has been released for ICI response prediction in non-small-cell lung cancer, renal cell carcinoma and malignant melanoma patients. Ongoing research aims to further expand the applicability to other tumour types. Read more on BiomeOne.

About BiomeDx®
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.


Presented poster: Deconfounding the intestinal microbiome signature of responders versus non-responders to immune checkpoint inhibitor therapies


Follow us on LinkedIn